Please use this identifier to cite or link to this item:
Title: Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study
Authors: Azevedo, George Dantas de
Prado, Maria Fernanda Massoni do
Ferriani, Rui Alberto
Reis, Rosana Maria dos
Berezowski, Aderson Tadeu
Ribeiro, Tatiane Flores
Silva, Ester
Maranhão, Técia Maria de Oliveira
Sá, Marcos Felipe Silva de
Keywords: Menopause;Climactery;Selective estrogen receptor modulator;Raloxifene;Doppler;Endometrium
Issue Date: 2004
Citation: AZEVEDO, G. D.; PRADO, M. F. M. ; FERRIANI, R. A.; REIS, R. M.; BEREZOWSKI, A. T.; RIBEIRO, T. F.; SILVA, E.; MARAMHÃO, T. M. O.; SA. M. F. S. (2004)
Abstract: Objective:To monitor the effects of raloxifene therapy on the uterus of postmenopausalwomen by transvaginal ultrasonography and color flow Doppler. Methods: Twenty-five healthy postmenopausal women were enrolled in this prospective longitudinal study performed at Department of Gynecology and Obstetrics, Faculty of Medicine of Ribeirão Preto. The patients were treated with raloxifene hydrochloride (60 mg per day) for 6 months. All were submitted to transvaginal ultrasound examination with color flow Doppler (ATL-HDI 3000 equipment) before the beginning and after 1, 3 and 6 months of treatment. Resistance index (RI) and pulsatility index (PI) of the uterine arteries were determined by the Doppler method, being considered as indicators of uterine perfusion. The following variables were analyzed: endometrial thickness, uterine volume, RI, and PI. Data were analyzed statistically by repeated-measures analysis of variance. Results: Before treatment, endometrial thickness was 3.38 ± 0.73 mm, and similar values were observed after 1, 3 and 6 months of treatment (3.04 ± 0.82; 3.3 ± 0.83; and 3.37 ± 0.79, respectively) (P > 0.05). No significant differences in uterine volume were observed between the pre- and post-treatment periods. Uterine artery perfusion as indicated by RI and PI measured by Doppler also showed no significant variation, with a high impedance flow being maintained throughout treatment. Conclusions: In the group studied here, raloxifene treatment at the dose of 60 mg per day for 6 months did not induce significant changes in endometrial thickness, uterine volume or uterine artery perfusion, confirming that short-term raloxifene treatment does not affect the uterus of postmenopausal women
Description: AZEVEDO, George Dantas de et al. Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study. Maturitas, Amsterdam, v.47, n.3, p.195-200, 2004
Appears in Collections:CCS - DTG - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
RaloxifeneTherapyAffect_Azevedo_2004.pdf68,75 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.